The Arora Report

IMMUNOGEN (IMGN): WHAT TO DO NOW

September 26, 2011

ImmunoGen (IMGN ) stock has moved up sharply on the news that T-DM1 produced by ImmunoGen improved survival in patients suffering from HER2-Positive Metastatic Breast Cancer.

T-DM1 contains DM1 cancer cell killing agent produced by ImmunoGen attached to an HER-2 targeting antibody.

This development is mostly already in the stock price of ImmunoGen.

If and when six screens of the ZYX Change Method are satisfied, we will issue a buy signal on the Real Time Feed of the ZYX Buy Change Alert.

IMGN

Subscribe to 'Generate Wealth'

Free Forever

More To Explore

AVOID THE MISTAKE COUNTLESS INVESTORS AND ADVISORS ARE MAKING, ORAL WEIGHT LOSS DRUG IS ALMOST HERE

April 17, 2025

A SUCCESS STORY — DYNAMIC HEDGING IS INVESTORS’ BEST FRIEND IN THIS STOCK MARKET

April 16, 2025

30 Day Free Trial

Cancel within 30 days and you owe nothing

When you take a FREE 30 day trial, you get access to powerful techniques used by billionaires and hedge funds to grow richer. You can continue to use these powerful techniques to grow richer even if you cancel your subscription. You come out ahead by subscribing no matter how you look at it.